Cantitate/Preț
Produs
Total produse
Vezi coșul
Handbook of Incretin-based Therapies in Type 2 Diabetes de Stephen Gough

Handbook of Incretin-based Therapies in Type 2 Diabetes

Editat de Stephen Gough
en Limba Engleză Paperback – 16 iun 2016
This concise handbook provides an overview of incretin-based therapies and guidance for incorporating them into the treatment of type 2 diabetes. Chapters include landmark clinical trials and international treatment guidelines in order to update readers with all major advances in the field. An ideal resource for medical professionals that treat patients with type 2 diabetes in hospital and clinical settings.
Citește tot Restrânge

Preț: 34294 lei

Preț vechi: 36099 lei
-5% Nou

Puncte Express: 514
Preț estimativ în valută:
6563€ • 6924$ • 5470£

Carte tipărită la comandă

Livrare economică 02-16 ianuarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783319089812
ISBN-10: 3319089811
Pagini: 100
Ilustrații: IX, 92 p. 20 illus., 16 illus. in color.
Dimensiuni: 127 x 203 x 11 mm
Greutate: 0.11 kg
Ediția:1st ed. 2016
Editura: Springer International Publishing
Colecția Adis
Locul publicării:Cham, Switzerland

Public țintă

Professional/practitioner

Cuprins

1. Introduction and disease overview
References

2. Incretin hormones as a target for therapy
Incretin hormone physiology 
The incretin-producing cell
GIP and GLP-1 action
Measurement of the incretin hormones
Incretin action in healthy individuals
Incretin action in patients with type 2 diabetes
Therapeutics application
References

3. Glucagon-like peptide receptor agonists 
Introduction 
GLP-1 receptor agonists 
Extrapancreatic effects GLP-1 receptor agonists 
Pancreatic safety 
Perspectives 
References 

4. Dipeptidyl peptidase-4 inhibitors 
Introduction 
Pharmacokinetics and pharmacodynamics 
Efficacy 
Combination therapy 
Use in specific patient populations 
Conclusions 
References 

5. Global position and recommendations for use 
Introduction 
American Association of Clinical Endocrinologists/American College of Endocrinology
American Diabetes Association /European Association for the Study of Diabetes
International Diabetes Federation 
National Institute of Health and Care Excellence 
Using incretin-based therapies in clinical practice 
Availability and licences 
References 

6. Future and emerging therapies 
Introduction 
Once-weekly agents under investigation 
Subcutaneous implants 
Investigational DPP-4 inhibitors and fixed-dose combination with SGLT2 inhibitors 
Other indications for incretin therapies
DPP-4 inhibitors
References                                                                                                                                                                                                            

Recenzii

                                                                                                                                                                               

Notă biografică

Stephen Gough is Professor of Diabetes at the University ofOxford and Consultant Physician at the Oxford University Hospitals NHS Trust.Professor Gough graduated in medicine from Leeds University Medical School,where he was later awarded a higher degree Doctorate in Medicine, which focusedon cardiac dysfunction and abnormalities in coagulation and fibrinolysispresent at the time of diagnosis of type 2 diabetes. He is currently based atthe Oxford Centre for Diabetes, Endocrinology and Metabolism, where he is apracticing clinician in diabetes. His research interests and ongoing researchstudies include translational aspects of diabetes, with a focus on thephysiology of islet cell and whole organ pancreas transplantation, incretinbiology, and incretin therapies in diabetes. Professor Gough has previously hada strong interest in the genetic susceptibility to autoimmunity and this workhas been extended into his work on pancreas transplantation. He has publishedhis research extensively in peer-reviewed journals and has contributed to manynational and international conferences and books on diabetes. In recent years,Professor Gough has helped develop translation research in diabetes in Oxfordthrough a number of local and national initiatives, including the OxfordBiomedical Research Centre, and he is Clinical Lead in Diabetes for the OxfordAcademic Health Science Network and the Oxford Local Clinical Research Network. Addendum
Since editing this book, Professor Gough has taken up theposition of Senior Principal Clinical Scientist with Novo Nordisk. He continuesas Visiting Professor of Diabetes at the University of Oxford and HonoraryConsultant with the Oxford University Hospitals NHS Trust.                                                                                                                                                                                                 

Textul de pe ultima copertă

                                                                                                                         

Caracteristici

A concise overview of ground breaking novel incretin-based therapies, including GLP-1 receptor agonists and DPP-4 inhibitors
Ideal for busy clinicians who encounter patients with type 2 diabetes on a daily basis and are interested in a clinically-applicable introduction to incretin-based therapies
Includes the most up-to-date clinical guidelines, recent clinical trials and expert discussions of established and emerging therapies for patients with type 2 diabetes
Includes supplementary material: sn.pub/extras